For research use only
| Cat No. | ABC-TC0402 |
| Product Type | Human Pancreas Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Disease | Pancreatic Ductal Adenocarinoma |
| Product Code | HPAF II; HPAFII; HPAF-2; HPAF2; HPAF/CD18; CD18/HPAF; HPAF-II/CD18; CD-18; CD18; CD 18 |
HPAF-II cell line offers a human pancreatic adenocarcinoma model for cancer biology, drug screening, and functional cellular pathway studies.
HPAF-II is a human pancreatic adenocarcinoma cell line derived from the ascitic fluid of a male. This cell line grows as adherent epithelial cells forming irregular monolayers. The cells express mucin genes Muc1 and Muc4 and secrete high levels of Muc1 glycoprotein. It forms well-differentiated adenocarcinomas in athymic mice, closely resembling the original tumor. HPAF-II is widely used in studies of pancreatic cancer biology, chemoresistance mechanisms, epithelial-mesenchymal transition (EMT), and targeted inhibitor evaluation. It also serves as a model for drug screening and for in vitro investigation of tumor-stroma interactions in pancreatic cancer. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | HPAF II; HPAFII; HPAF-2; HPAF2; HPAF/CD18; CD18/HPAF; HPAF-II/CD18; CD-18; CD18; CD 18 |
| Species | Human |
| Cat.No | ABC-TC0402 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Pancreas |
| Disease | Pancreatic Ductal Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Pancreas Cancer Cell Lines |
HPAF-II cells are applied in pancreatic cancer research involving Muc1/Muc4 biology, chemoresistance, EMT changes, and tumor-stroma interaction modeling. These cells also form well-differentiated adenocarcinomas in xenograft models, facilitating translational drug testing and targeted therapy evaluation. Their ability to recapitulate key features of human pancreatic tumors makes them a valuable tool for bridging preclinical and clinical research in this challenging disease area.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
